Clinical Trials Logo

Clinical Trial Summary

The study is planned to be conducted in 2 parts. The first part (open label, multi-center, non-controlled) of the study will estimate a dose that would provide a mycophenolic acid (MPA) exposure in pediatric participant that is comparable to that achieved in adult liver transplant participants receiving the approved dose of mycophenolate mofetil (MMF, CellCept). The second part (open-label, multi-center, single-arm Phase IV study) of the study will provide the pharmacokinetics, efficacy and safety profile of the proposed dose in the immediate post-transplant period. This study will be conducted at two centers based in the United States of America. Twelve pediatric transplant participants receiving a first liver allograft from a cadaveric or living donor will be enrolled in this study. Stable pediatric liver transplant participants who are at least 6 months post-transplant and who were already receiving stable dose of MMF in combination with cyclosporine will be enrolled into the study. Participants should have received stable MMF dose according to center practice for at least seven days in order to get steady state pharmacokinetics (PK). Participants also should have received stable concomitant doses of cyclosporine (for at least 2 days) and corticosteroids per center practice. Participants will be aged between 9 months and 12 years, with at least 6 participants greater than or equal to (>/=) 9 months and less than (<) 36 months, of whom at least 2 will be <24 months.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02630563
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Terminated
Phase Phase 4
Start date May 2003
Completion date January 2005

See also
  Status Clinical Trial Phase
Recruiting NCT04518332 - Intraoperative Cerebral and Renal Tissue Oxygen Saturation and Pediatric Living Donor Liver Transplantation Prognosis.
Recruiting NCT04792788 - NAVA vs PSV Ventilation During Weaning From Mechanical Ventilation in Children After Liver Transplantation N/A
Recruiting NCT02957552 - Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation Phase 1
Recruiting NCT02064777 - Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation Phase 4
Recruiting NCT03494595 - Thromboelastometry as a Predictor of Thrombotic Complications During Pediatric Recipient Liver Transplantation
Not yet recruiting NCT05825703 - Incidence and Risk Factors of Prolonged Post-Operative Mechanical Ventilation